Salivary gland toxicity after radioiodine therapy for thyroid cancer
Salivary gland toxicity after radioiodine therapy for thyroid cancer
复制标题
DOI:
10.1016/j.clon.2006.11.005
复制
发表时间:
2007-02-01
影响因子:
3.4
通讯作者:
Harmer, C.
中科院分区:
文献类型:
--
作者:
Hyer, S.;Kong, A.;Harmer, C.
Aims: Salivary gland toxicity is a common, but not widely appreciated, adverse effect of high-dose radioiodine (I-131). This study was carried out to determine the incidence of symptoms of salivary gland damage after I-131 treatment for differentiated thyroid cancer.Materials and methods: This was a prospective study of 76 consecutive patients attending thyroid cancer treatment. Symptoms of salivary gland damage (dry mouth, pain and swelling) were assessed during hospital admission and at follow-up visits. Additionally, a retrospective analysis was carried out of patients recorded in our database as having chronic salivary gland swelling after I-131 ablation.Results: Twenty patients (26%) developed salivary gland toxicity, 11 (15%) had symptoms within the first 48 h, continuing for 12 months in seven of these patients. The onset of toxicity in a further nine (12%) patients with persistent symptoms did not occur until 3 months after therapy. In total, 16 (21%) patients had evidence of chronic toxicity, typically xerostomia, at 12 months. Toxicity was more common after repeated I-131 administration. After searching our thyroid cancer database, we identified an additional five patients to have chronic salivary gland swelling (chronic sialadenitis or pleomorphic adenoma) 20 months to 23 years after I-131.Conclusions: Pain, swelling and dry mouth occurred frequently after I-131, with some developing symptoms months or years after administration. Early recognition of salivary gland complications may help to reduce morbidity in these patients.